Propel testing excellence with Mayo Clinic quality
Mayo Clinic Laboratories is a one-stop laboratory solution, offering commercial laboratories a vast testing menu, unparalleled customer service, and optimized processes. We work collaboratively with partners to assess their needs, providing the testing they need to expand into new areas and meet their business goals.
As the reference lab for Mayo Clinic, we’ve developed robust logistics and testing protocols applied uniformly for all specimens received, no matter their geographic origin. Whether you send us one test order or thousands, each sample receives the same treatment and level of care, ensuring superior results that help our partners better serve their clients.
“Our clients want personal experiences. They want someone to answer the phone. They want someone to provide answers when they're looking for results of a sample sent a couple days ago. and we deliver those answers.”
Angie Reese-Davis, director of operations, logistics, and specimen services, Mayo Clinic Laboratories
Our difference
News and updates
The latest
In this episode of the “Leveraging the Laboratory” podcast, Jane Hermansen, outreach manager at Mayo Clinic Laboratories, welcomes Chelsea Conn, Mayo Clinic Laboratories’ director of regulatory affairs. Together, they break down the latest regulatory changes and share actionable strategies to help outreach programs stay informed and prepared.
Today's highlights include: Long COVID affects more older adults, US has a new dominant COVID-19 strain, and Gianrico Farrugia explains how we can transform healthcare by moving from pipeline to platform.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. In this episode, Dr. Morice and Dr. Pritt review the VALID Act — a piece of legislation currently under consideration in Congress that could lead to significant changes in the oversight of clinical laboratories in the U.S.
Top highlights include: Monoclonal and oligoclonal anti-Platelet Factor 4 antibodies mediate VITT.
Elitza Theel, Ph.D., director of the Infectious Diseases Serology Lab at Mayo Clinic, joins the "Answers From the Lab" podcast for a discussion with Bobbi Pritt, M.D. about tick-borne disease testing. In this episode, Dr. Theel and Dr. Pritt look at emerging tick-borne illnesses, the tests available to detect these infections, and how to prevent them.
Topics include: COVID-19 update, tips for navigating a return to work with long COVID, and COVID-19 booster vaccinations extended to kids 5-11.
Today's highlights include: US at risk of COVID-19 drug shortages this summer, Rochester startup Vyriad developing cancer-fighting viruses, and CDC expresses concern about possibility of undetected monkeypox spread in U.K.
In this special episode of “Lab Medicine Rounds,” Isabella Dishong, president of PathSIG and fourth-year medical student, asks Dr. Justin Kreuter questions from the PathSIG community of medical students who matched into pathology residency.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins the "Answers From the Lab" podcast for his weekly leadership update with Bobbi Pritt, M.D. In this episode, Dr. Morice and Dr. Pritt discuss legislation under consideration in Congress that could have significant impact on laboratory medicine in the U.S.
This “phlebotomy webinar” will provide basic information on blood compatibility, the consequences of incompatibility and the recognition of an acute hemolytic transfusion reaction.
In her role as a proposal writer, Lisa Wortman Raring helps show clients everything Mayo Clinic Laboratories has to offer, making it clear how the organization can best meet their needs and the needs of their patients.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.
Top highlights include: Rapid exclusion of acute myocardial injury and infarction with a high sensitivity cardiac troponin T in the emergency department.